Tenatoprazole
 | |
| Systematic (IUPAC) name | |
|---|---|
| (RS)-3-Methoxy-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraene | |
| Clinical data | |
| Oral | |
| Pharmacokinetic data | |
| Metabolism | Hepatic (CYP2C19-mediated) |
| Half-life | 4.8 to 7.7 hours |
| Identifiers | |
113712-98-4  | |
| None | |
| PubChem | CID 636411 |
| ChemSpider |
552196 |
| UNII |
RE0689TX2K |
| Chemical data | |
| Formula | C16H18N4O3S |
| 346.405 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]:22
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]:27 and again in 2012.[3]:17
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]
References
- ↑ DataMonitor. March 2003. Gastrointestinal Disease Update: Digestive Disease Week 2003
- ↑ Economic Times. 3 March, 2011. Investors unwilling to forgive Wockhardt, promoter for failings
- ↑ 3.0 3.1 Mitsubishi Tanabe Pharma State of New Product Development (as of May 8, 2012)
- ↑ Mitsubishi Tanabe Pharma FY2007 Interim Financial Results
- ↑ Li H et al. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013 Jan;23(1):99-111. PMID 23205582
| ||||||||||||||||||||||||||||||||||||||||||||